Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer

被引:0
|
作者
Ping Fan
V. Craig Jordan
机构
[1] Unit 1354,Department of Breast Medical Oncology
[2] The University of Texas MD Anderson Cancer Center,undefined
来源
Targeted Oncology | 2022年 / 17卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Estrogen receptor α (ERα) is a target for the treatment of ER-positive breast cancer patients. Paradoxically, it is also the initial site for estrogen (E2) to induce apoptosis in endocrine-resistant breast cancer. How ERα exhibits distinct functions, in different contexts, is the focus of numerous investigations. Compelling evidence demonstrated that unfolded protein response (UPR) is closely correlated with ER-positive breast cancer. Treatment with antiestrogens initially induces mild UPR through ERα with activation of three sensors of UPR—PRK-like endoplasmic reticulum kinase (PERK), inositol-requiring enzyme 1α (IRE1α), and activating transcription factor 6 (ATF6)—in the endoplasmic reticulum. Subsequently, these sensors interact with stress-associated transcription factors such as c-MYC, nuclear factor-κB (NF-κB), and hypoxia-inducible factor 1α (HIF1α), leading to acquired endocrine resistance. Paradoxically, E2 further activates sustained secondary UPR via ERα to induce apoptosis in endocrine-resistant breast cancer. Specifically, PERK plays a key role in inducing apoptosis, whereas IRE1α and ATF6 are involved in endoplasmic reticulum stress-associated degradation after E2 treatment. Furthermore, persistent activation of PERK deteriorates stress responses in mitochondria and triggers of NF-κB/tumor necrosis factor α (TNFα) axis, ultimately determining cell fate to apoptosis. The discovery of E2-induced apoptosis has clinical relevance for treatment of endocrine-resistant breast cancer. All of these findings demonstrate that ERα and associated UPR are double-edged swords in therapy for ER-positive breast cancer, depending on the duration and intensity of UPR stress. Herein, we address the mechanistic progress on how UPR leads to endocrine resistance and commits E2 to inducing apoptosis in endocrine-resistant breast cancer.
引用
收藏
页码:111 / 124
页数:13
相关论文
共 50 条
  • [31] Role of Androgen Excess in the Development of Estrogen Receptor-positive and Estrogen Receptor-negative Breast Cancer
    Secreto, Giorgio
    Zumoff, Barnett
    ANTICANCER RESEARCH, 2012, 32 (08) : 3223 - 3228
  • [32] Estrogen receptor α is involved in the regulation of ITGA8 methylation in estrogen receptor-positive breast cancer
    Wu, Jingxun
    Cheng, Jianghong
    Zhang, Fuxing
    Luo, Xianyang
    Zhang, Zhiming
    Chen, Shuai
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (16)
  • [33] Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
    Nagaraj, Gayathri
    Ma, Cynthia
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (02) : 231 - 242
  • [34] MicroRNAs in estrogen receptor-positive and -negative breast cancer cells
    Miyamoto, Kazuaki
    Miyamoto, Haruko
    CANCER RESEARCH, 2009, 69
  • [35] The impact of CBP expression in estrogen receptor-positive breast cancer
    Wafaa S. Ramadan
    Iman M. Talaat
    Mahmood Y. Hachim
    Annette Lischka
    Timo Gemoll
    Raafat El-Awady
    Clinical Epigenetics, 2021, 13
  • [36] Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
    Gayathri Nagaraj
    Cynthia Ma
    Breast Cancer Research and Treatment, 2015, 150 : 231 - 242
  • [37] A novel oncogenic enhancer of estrogen receptor-positive breast cancer
    Bao, Chunjie
    Duan, Jialun
    Xie, Ying
    Liu, Yixuan
    Li, Peishan
    Li, Jianwei
    Zhao, Huihui
    Guo, Haitao
    Men, Yanchen
    Ren, Yuxin
    Xu, Jiarui
    Wang, Guiling
    Lu, Wanliang
    MOLECULAR THERAPY NUCLEIC ACIDS, 2022, 29 : 836 - 851
  • [38] Effect of farrerol on the proliferation of estrogen receptor-positive breast cancer by downregulating oncogenic genes with estrogen receptor response elements.
    Lu, Xiao-Qing
    Yang, Rui
    Zhang, Jia-Qian
    Zhang, Shengxiao
    Zhang, Huan-Hu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Update on estrogen receptor-positive breast cancer risk reduction
    Vogel V.G.
    Current Breast Cancer Reports, 2011, 3 (3) : 156 - 164
  • [40] Late Recurrences After Estrogen Receptor-Positive Breast Cancer
    Narod, Steven A.
    Giannakeas, Vasily
    Sopik, Victoria
    JAMA ONCOLOGY, 2020, 6 (02) : 301 - +